Endocannabinoid Signaling in the Central Amygdala and Bed Nucleus of the Stria Terminalis: Implications for the Pathophysiology and Treatment of Alcohol Use Disorder
- 2 August 2019
- journal article
- review article
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 43 (10) , 2014-2027
Abstract
High rates of relapse are a chronic and debilitating obstacle to effective treatment of alcohol use disorder (AUD); however, no effective treatments are available to treat symptoms induced by protracted abstinence. In the first part of this 2‐part review series, we examine the literature supporting the effects of alcohol exposure within the extended amygdala (EA) neural circuitry. In Part 2, we focus on a potential way to combat negative affect associated with AUD, by exploring the therapeutic potential of the endogenous cannabinoid (eCB) system. The eCB system is a potent modulator of neural activity in the brain, and its ability to mitigate stress and negative affect has long been an area of interest for developing novel therapeutics. This review details the recent advances in our understanding of eCB signaling in 2 key regions of the EA, the central nucleus of the amygdala and the bed nucleus of the stria terminalis (BNST), and their role in regulating negative affect. Despite an established role for EA eCB signaling in reducing negative affect, few studies have examined the potential for eCB‐based therapies to treat AUD‐associated negative affect. In this review, we present an overview of studies focusing on eCB signaling in EA and cannabinoid modulation on EA synaptic activity. We further discuss studies suggesting dysregulation of eCB signaling in models of AUD and propose that pharmacological augmentation of eCB could be a novel approach to treat aspects of AUD. Lastly, future directions are proposed to advance our understanding of the relationship between AUD‐associated negative affect and the EA eCB system that could yield new pharmacotherapies targeting negative affective symptoms associated with AUD.Keywords
Funding Information
- National Institutes of Health (AA026186, AA019455)
This publication has 132 references indexed in Scilit:
- Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague–Dawley ratsNeuroscience, 2012
- Endocannabinoid signaling in the amygdala: anatomy, synaptic signaling, behavior, and adaptations to stressNeuroscience, 2012
- Long-term effects of juvenile nicotine exposure on abstinence-related social anxiety-like behavior and amygdalar cannabinoid receptor 1 (CB1R) mRNA expression in the novelty-seeking phenotypeBehavioural Brain Research, 2012
- Dual Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Blockade Produces THC-Like Morris Water Maze Deficits in MiceACS Chemical Neuroscience, 2012
- TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrusNature Neuroscience, 2010
- Short-Term Adaptation of Conditioned Fear Responses Through Endocannabinoid Signaling in the Central AmygdalaNeuropsychopharmacology, 2010
- Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicidesJournal of Psychiatric Research, 2010
- The Endocannabinoid System Tonically Regulates Inhibitory Transmission and Depresses the Effect of Ethanol in Central AmygdalaNeuropsychopharmacology, 2010
- Repeated Homotypic Stress Elevates 2-Arachidonoylglycerol Levels and Enhances Short-Term Endocannabinoid Signaling at Inhibitory Synapses in Basolateral AmygdalaNeuropsychopharmacology, 2009
- Multiple pathways involved in the biosynthesis of anandamideNeuropharmacology, 2008